Salivary Gland Neoplasms
Conditions
Brief summary
The purpose of the study is to evaluate the overall response rate (ORR) of apalutamide in combination with a gonadotropin-releasing hormone (GnRH) agonist in participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC).
Interventions
DRUGApalutamide
Apalutamide 240 mg (4\*60-mg tablets) will be administered orally once daily with or without food.
DRUGGnRH Agonist
A stable regimen of goserelin 3.6 mg will be administered as a GnRH agonist.
Sponsors
Janssen Pharmaceutical K.K.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed salivary gland carcinoma (SGC) by local pathology * Androgen receptor (AR) expressing SGC: Local testing of AR-positivity will be performed as standard of care for the eligibility confirmation. AR-positivity will be defined according to immunohistochemistry (IHC) staining of tumor tissue with at least 1 percent (%) of cell nuclei staining positive. Tissue should be available for the central confirmation of AR-positivity, but the central result of AR positivity will not be required for initiating the study intervention * Locally advanced or recurrent/metastatic SGC * Measurable lesion(s) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
Exclusion criteria
* Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to first dose. Treatment with a drug that has a short half life (t1/2) (for example, less than \[\<\] 1 day) may be eligible in accordance with the discussion with the sponsor's medical monitor * Radiographically confirmed brain metastases. In case of history of brain metastases that were previously treated and not recurred for at least 6 months, they are considered eligible * Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less (except for all grade alopecia, and for peripheral neuropathy, and hypothyroidism stable on hormone replacement therapy to be Grade 2 or less). If corticosteroids are administered for any reasons such as the management of toxicities due to prior therapies, the dose must be tapered until 10 milligram (mg)/day or less of prednisolone and contact the sponsor's medical monitor on an individual basis prior to the first dose * Active or symptomatic viral hepatitis or chronic liver disease; ascites or bleeding disorders secondary to hepatic dysfunction * History of seizure or any condition that may predispose to seizure (including, but not limited to, prior stroke, transient ischemic attack, or loss of consciousness less than or equal to \[\<=\] 1 year prior to first dose; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect) * Treatment with drugs known to lower the seizure threshold within 4 weeks prior to first dose * Known or suspected contraindications or hypersensitivity to apalutamide, gonadotropin-releasing hormone agonist (GnRHa) analogues or any of the components of the formulations * Received prior ADT including a GnRH analogue, AR blocker such as bicalutamide, enzalutamide or 17alpha-hydroxylase-17,20-lyase (CYP17) inhibitor such as abiraterone acetate etc. Chemotherapy, radiation, or surgery as part of curative intent therapy are allowed so long as prior therapy did not include ADT. Prior chemotherapy, targeted cancer therapy or immunotherapy within 1 week or 4 half-lives whichever is longer, before the first administration of study drug. For agents with long half-lives, the maximum required time since last dose is 2 weeks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | Up to 13 months | Overall response rate (ORR) was defined as the percentage of participants who achieve partial response (PR) or better according to the response evaluation criteria in solid tumors (RECIST) version1.1, including with either confirmed best overall response of complete response (CR) or PR during the study. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR is defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, in absence of new lesions or unequivocal progression of non-target lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Benefit Rate (CBR) | Up to 13 months | Clinical benefit rate (CBR) was defined as the percentage of participants who achieved a confirmed best overall response of CR, PR, or stable disease (SD) for at least 24 weeks based on RECIST version 1.1 during the study (and prior to subsequent therapy if any). CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, in absence of new lesions or unequivocal progression of non-target lesions. SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. |
| Disease Control Rate (DCR) | Up to 13 months | DCR was defined as the percentage of participants who achieved a confirmed best overall response of CR, PR, or SD based on RECIST version 1.1 during the study (and prior to subsequent therapy if any). CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, in absence of new lesions or unequivocal progression of non-target lesions. SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. |
| Progression-free Survival (PFS) as Assessed by ICRR | Up to 13 months | PFS was defined as the time from the date of the initial dose of study intervention to the date of first documented disease progression as defined in the RECIST version 1.1, or death due to any cause, whichever occurred first. Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. |
| Overall Survival (OS) | Up to 13 months | Overall survival (OS) was defined as the time from the date of the initial dose of study intervention to the date of the participant's death. |
| Time to Response (TTR) | Up to 13 months | TTR was defined among responders (with a CR or PR) as the time between date of the initial dose of study intervention and the first efficacy evaluation that the participant had met all criteria for CR or PR. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, in absence of new lesions or unequivocal progression of non-target lesions. |
| Duration of Response (DoR) | Up to 13 months | DoR calculated among responders from the date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease as defined in RECIST version 1.1 or death, whichever occurred first. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, in absence of new lesions or unequivocal progression of non-target lesions. |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Up to 13 months | Number of participants with TEAEs were reported. Treatment-emergent adverse events (TEAEs) for the treatment phase included events with an onset date/time on or after the start of study intervention through the day of last dose plus 30 days were considered as treatment-emergent. |
| Plasma Concentration of Apalutamide | Day 1 (predose) of Cycles 2 to 6 (each cycle was of 28 days) | Plasma concentration of apalutamide was reported. |
| Plasma Concentration of N-desmethyl Apalutamide | Day 1 (predose) of Cycles 2 to 6 (each cycle was of 28 days) | Plasma concentration of N-desmethyl Apalutamide was reported. |
Countries
Japan
Contacts
STUDY_DIRECTORJanssen Pharmaceutical K.K., Japan Clinical Trial
Janssen Pharmaceutical K.K.
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Apalutamide + Goserelin Participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC) received apalutamide 240 milligrams (mg) (4\*60 mg tablets) orally once daily with or without food in combination with stable regimen of goserelin 3.6 mg administered subcutaneously once per cycle (each cycle is of 28 days) as a gonadotropin-releasing hormone (GnRH) agonist, until disease progression, unacceptable toxicity, death, or end of the study. | 31 |
| Total | 31 |
Baseline characteristics
| Characteristic | Apalutamide + Goserelin |
|---|---|
| Age, Continuous | 65 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 31 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 31 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 30 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 4 / 31 |
| other Total, other adverse events | 28 / 31 |
| serious Total, serious adverse events | 5 / 31 |
Outcome results
Primary
Overall Response Rate (ORR)
Overall response rate (ORR) was defined as the percentage of participants who achieve partial response (PR) or better according to the response evaluation criteria in solid tumors (RECIST) version1.1, including with either confirmed best overall response of complete response (CR) or PR during the study. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR is defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, in absence of new lesions or unequivocal progression of non-target lesions.
Time frame: Up to 13 months
Population: Response evaluable set included all participants who were androgen receptor (AR) positive by local test and were confirmed evaluable by independent central radiology review (ICRR) and also, who received at least 1 dose of study drug and had at least 1 postbaseline disease assessment or died due to disease progression before first postbaseline disease assessment. Here, 'N' (number of participants analyzed) included 24 response evaluable participants who were analyzed for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Apalutamide + Goserelin | Overall Response Rate (ORR) | 25 percentage of participants |
Secondary
Clinical Benefit Rate (CBR)
Clinical benefit rate (CBR) was defined as the percentage of participants who achieved a confirmed best overall response of CR, PR, or stable disease (SD) for at least 24 weeks based on RECIST version 1.1 during the study (and prior to subsequent therapy if any). CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, in absence of new lesions or unequivocal progression of non-target lesions. SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
Time frame: Up to 13 months
Population: Response evaluable set included all participants who were AR positive by local test and who were confirmed evaluable by an ICRR and also, all participants who received at least 1 dose of study intervention and who had at least 1 postbaseline disease assessment or died due to disease progression before the first postbaseline disease assessment. Here, 'N' (number of participants analyzed) included 24 response evaluable participants who were analyzed for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Apalutamide + Goserelin | Clinical Benefit Rate (CBR) | 50 percentage of participants |
Secondary
Disease Control Rate (DCR)
DCR was defined as the percentage of participants who achieved a confirmed best overall response of CR, PR, or SD based on RECIST version 1.1 during the study (and prior to subsequent therapy if any). CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, in absence of new lesions or unequivocal progression of non-target lesions. SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
Time frame: Up to 13 months
Population: Response evaluable set included all participants who were AR positive by local test and who were confirmed evaluable by an ICRR and also, all participants who received at least 1 dose of study intervention and who had at least 1 postbaseline disease assessment or died due to disease progression before the first postbaseline disease assessment. Here, 'N' (number of participants analyzed) included 24 response evaluable participants who were analyzed for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Apalutamide + Goserelin | Disease Control Rate (DCR) | 70.8 percentage of participants |
Secondary
Duration of Response (DoR)
DoR calculated among responders from the date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease as defined in RECIST version 1.1 or death, whichever occurred first. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, in absence of new lesions or unequivocal progression of non-target lesions.
Time frame: Up to 13 months
Population: Population analyzed included response evaluable set amongst who were responders (CR or PR).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Apalutamide + Goserelin | Duration of Response (DoR) | NA months |
Secondary
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs were reported. Treatment-emergent adverse events (TEAEs) for the treatment phase included events with an onset date/time on or after the start of study intervention through the day of last dose plus 30 days were considered as treatment-emergent.
Time frame: Up to 13 months
Population: Safety analysis set included all participants who received at least 1 dose of study intervention.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Apalutamide + Goserelin | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 28 Participants |
Secondary
Overall Survival (OS)
Overall survival (OS) was defined as the time from the date of the initial dose of study intervention to the date of the participant's death.
Time frame: Up to 13 months
Population: Treated analysis set included all participants who received at least 1 dose of study intervention.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Apalutamide + Goserelin | Overall Survival (OS) | NA months |
Secondary
Plasma Concentration of Apalutamide
Plasma concentration of apalutamide was reported.
Time frame: Day 1 (predose) of Cycles 2 to 6 (each cycle was of 28 days)
Population: Pharmacokinetics analysis set included all participants with at least 1 apalutamide and/or N-desmethyl apalutamide concentration data after the first study intervention administration. Here, 'N' (number of participants analyzed) specifies all participants who were evaluated for this outcome measure (OM). Here, 'n' (number analyzed) specifies the number of participants evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Apalutamide + Goserelin | Plasma Concentration of Apalutamide | Cycle 02 Day 1, Predose | 4.67 micrograms per milliliter (mcg/mL) | Standard Deviation 1.19 |
| Apalutamide + Goserelin | Plasma Concentration of Apalutamide | Cycle 03 Day 1, Predose | 4.32 micrograms per milliliter (mcg/mL) | Standard Deviation 1.35 |
| Apalutamide + Goserelin | Plasma Concentration of Apalutamide | Cycle 04 Day 1, Predose | 4.05 micrograms per milliliter (mcg/mL) | Standard Deviation 1.46 |
| Apalutamide + Goserelin | Plasma Concentration of Apalutamide | Cycle 05 Day 1, Predose | 4.18 micrograms per milliliter (mcg/mL) | Standard Deviation 1.38 |
| Apalutamide + Goserelin | Plasma Concentration of Apalutamide | Cycle 06 Day 1, Predose | 4.16 micrograms per milliliter (mcg/mL) | Standard Deviation 1.52 |
Secondary
Plasma Concentration of N-desmethyl Apalutamide
Plasma concentration of N-desmethyl Apalutamide was reported.
Time frame: Day 1 (predose) of Cycles 2 to 6 (each cycle was of 28 days)
Population: Pharmacokinetics analysis set included all participants with at least 1 apalutamide and/or N-desmethyl apalutamide concentration data after the first study intervention administration. Here, 'N' (number of participants analyzed) specifies all participants who were evaluated for this OM. Here, 'n' (number analyzed) specifies the number of participants evaluated at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Apalutamide + Goserelin | Plasma Concentration of N-desmethyl Apalutamide | Cycle 02 Day 1, Predose | 7.19 mcg/mL | Standard Deviation 1.21 |
| Apalutamide + Goserelin | Plasma Concentration of N-desmethyl Apalutamide | Cycle 03 Day 1, Predose | 6.89 mcg/mL | Standard Deviation 1.56 |
| Apalutamide + Goserelin | Plasma Concentration of N-desmethyl Apalutamide | Cycle 04 Day 1, Predose | 6.29 mcg/mL | Standard Deviation 1.66 |
| Apalutamide + Goserelin | Plasma Concentration of N-desmethyl Apalutamide | Cycle 05 Day 1, Predose | 6.53 mcg/mL | Standard Deviation 1.81 |
| Apalutamide + Goserelin | Plasma Concentration of N-desmethyl Apalutamide | Cycle 06 Day 1, Predose | 6.40 mcg/mL | Standard Deviation 1.91 |
Secondary
Progression-free Survival (PFS) as Assessed by ICRR
PFS was defined as the time from the date of the initial dose of study intervention to the date of first documented disease progression as defined in the RECIST version 1.1, or death due to any cause, whichever occurred first. Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
Time frame: Up to 13 months
Population: Treated analysis set included all participants who received at least 1 dose of study intervention.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Apalutamide + Goserelin | Progression-free Survival (PFS) as Assessed by ICRR | 7.43 months |
Secondary
Time to Response (TTR)
TTR was defined among responders (with a CR or PR) as the time between date of the initial dose of study intervention and the first efficacy evaluation that the participant had met all criteria for CR or PR. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, in absence of new lesions or unequivocal progression of non-target lesions.
Time frame: Up to 13 months
Population: Population analyzed included response evaluable set amongst who were responders (CR or PR).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Apalutamide + Goserelin | Time to Response (TTR) | 1.87 months |